Preclinical evaluation of <sup>64</sup>Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor-positive breast cancer.

Breast Cancer Res · 2025 · PMC11889786 · PMID 40055744

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Unexpectedly, although the SUV max tended to be higher in metastasis-positive SLNs at 24 and 48 h in the ID/SD group, this finding did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Preclinical evaluation of &lt;sup&gt;64&lt;/sup&gt;Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor-positive breast cancer.

The sentences

Preclinical evaluation of <sup>64</sup>Cu-labeled cetuximab in immuno-PET for detecting sentinel lymph node metastasis in epidermal growth factor receptor-positive breast cancer.